EcoR1 Capital as of Dec. 31, 2019
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 43 positions in its portfolio as reported in the December 2019 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Prothena (PRTA) | 13.7 | $149M | 9.4M | 15.83 | |
| Fibrogen | 8.5 | $93M | 2.2M | 42.89 | |
| Dicerna Pharmaceuticals | 7.3 | $80M | 3.6M | 22.03 | |
| Xencor (XNCR) | 6.2 | $68M | 2.0M | 34.39 | |
| Kura Oncology (KURA) | 5.3 | $58M | 4.2M | 13.75 | |
| Ironwood Pharmaceuticals (IRWD) | 5.3 | $58M | 4.4M | 13.31 | |
| Arvinas Ord (ARVN) | 5.0 | $55M | 1.3M | 41.09 | |
| Assembly Biosciences | 4.5 | $49M | 2.4M | 20.46 | |
| Neoleukin Therapeutics | 4.4 | $48M | 3.9M | 12.32 | |
| Morphic Hldg (MORF) | 3.4 | $37M | 2.2M | 17.16 | |
| Prevail Therapeutics Ord | 3.3 | $36M | 2.2M | 15.83 | |
| Argenx Se (ARGX) | 3.0 | $32M | 202k | 160.52 | |
| Anaptysbio Inc Common (ANAB) | 2.9 | $32M | 2.0M | 16.25 | |
| Innate Pharma (IPHA) | 2.7 | $29M | 4.5M | 6.44 | |
| BioMarin Pharmaceutical (BMRN) | 2.4 | $26M | 313k | 84.55 | |
| Merus N V (MRUS) | 2.2 | $24M | 1.7M | 14.08 | |
| Atreca Inc Cl A (BCEL) | 2.1 | $23M | 1.5M | 15.47 | |
| ACADIA Pharmaceuticals (ACAD) | 2.0 | $21M | 500k | 42.78 | |
| Chiasma | 1.4 | $15M | 3.0M | 4.96 | |
| Harpoon Therapeutics | 1.2 | $13M | 909k | 14.79 | |
| Sage Therapeutics (SAGE) | 1.1 | $13M | 173k | 72.19 | |
| Ultragenyx Pharmaceutical (RARE) | 1.0 | $11M | 262k | 42.71 | |
| Selecta Biosciences | 1.0 | $11M | 4.6M | 2.38 | |
| Exicure | 0.9 | $10M | 3.5M | 2.86 | |
| Pieris Pharmaceuticals | 0.8 | $9.2M | 2.5M | 3.62 | |
| Fate Therapeutics (FATE) | 0.8 | $8.8M | 451k | 19.57 | |
| Mirati Therapeutics | 0.8 | $8.4M | 65k | 128.86 | |
| Arcus Biosciences Incorporated (RCUS) | 0.7 | $7.4M | 730k | 10.10 | |
| Evolus (EOLS) | 0.7 | $7.3M | 600k | 12.17 | |
| Eiger Biopharmaceuticals | 0.6 | $6.7M | 449k | 14.90 | |
| Savara (SVRA) | 0.6 | $6.4M | 1.4M | 4.48 | |
| Iovance Biotherapeutics (IOVA) | 0.5 | $5.9M | 214k | 27.68 | |
| Rubius Therapeutics | 0.5 | $5.0M | 526k | 9.50 | |
| Cyclerion Therapeutics | 0.5 | $4.9M | 1.8M | 2.72 | |
| X4 Pharmaceuticals | 0.4 | $4.4M | 415k | 10.70 | |
| Corvus Pharmaceuticals (CRVS) | 0.4 | $4.0M | 738k | 5.44 | |
| Aclaris Therapeutics (ACRS) | 0.4 | $3.9M | 2.1M | 1.89 | |
| Igm Biosciences (IGMS) | 0.3 | $3.8M | 100k | 38.16 | |
| Cytomx Therapeutics (CTMX) | 0.3 | $3.4M | 410k | 8.31 | |
| Tcr2 Therapeutics Inc cs | 0.3 | $3.4M | 240k | 14.28 | |
| Surface Oncology | 0.2 | $2.4M | 1.3M | 1.88 | |
| Vericel (VCEL) | 0.2 | $2.3M | 131k | 17.40 | |
| Urovant Sciences | 0.0 | $411k | 27k | 15.53 |
